Hormonal
GLP-1 receptor agonists improve glycemic control and promote weight loss in type 2 diabetes and obesity by stimulating glucose-dependent insulin secretion and reducing appetite, with efficacy superior to many existing therapies.
GLP-1 receptor agonists are highly effective treatments for Type 2 Diabetes and Obesity. They work by mimicking a natural hormone to increase insulin when blood sugar is high and reducing appetite. While they are usually given by injection (some are oral), they offer significant benefits in lowering blood sugar and losing weight, often more so than older diabetes medications. Common side effects like nausea are frequent but often improve over time. These drugs are not suitable for everyone, particularly those with a history of certain thyroid cancers or pancreatitis.
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)... GLP-1, as the endogenous agonist of GLP-1R, is a promising natural antidiabetic product due to its anorexigenic, insulinotropic, and weight-reducing effects.
Why this rating
The paper reviews multiple approved drugs (exenatide, liraglutide, semaglutide, tirzepatide) with extensive clinical trial data and FDA approvals.
Source
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wenwei Wan et al. · Molecules · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →